WaveMan · Form 4
Coleman Mark insider trades
> Search tickers & screens ⌘K
LIVE

Coleman Mark insider trades

Coleman Mark has filed 23 Form 4s with the SEC that we hold, all for Axsome Therapeutics, Inc. (AXSM), as Director. Across all of them we count 5 purchases worth $250.6K and 12 sales worth $12.3M reported on Form 4. In the last 12 months: 0 purchases ($0) and 5 sales ($8.2M). The largest single trade was a sale of 25,000 shares of Axsome Therapeutics, Inc. worth $4.0M, dated 2026-02-26. The first filing on our record is dated 2021-11-22 and the latest 2026-06-10.

Axsome Therapeutics, Inc. (AXSM)

Director · 23 filings · 17 purchases and sales
Trade dateCodeSharesValue as filedFiled
2021-11-18P, purchase reported on Form 41,021$35.8K2021-11-22
2021-11-18P, purchase reported on Form 4409$14.3K2021-11-22
2023-09-15S, sale reported on Form 418,572$1.4M2023-09-15
2023-09-15S, sale reported on Form 411,016$828.3K2023-09-15
2024-05-28S, sale reported on Form 45,249$394.8K2024-05-29
2024-05-29S, sale reported on Form 45,248$394.3K2024-05-29
2025-05-20S, sale reported on Form 43,000$322.5K2025-05-20
2025-05-27S, sale reported on Form 43,750$395.5K2025-05-29
2025-05-28S, sale reported on Form 43,750$387.9K2025-05-29
2025-09-08P, purchase reported on Form 4287$36.5K2025-09-09
2025-09-08P, purchase reported on Form 4488$62.2K2025-09-09
2025-09-08P, purchase reported on Form 4800$101.8K2025-09-09
2026-02-26S, sale reported on Form 425,000$4.0M2026-02-27
2026-05-29S, sale reported on Form 46,000$1.4M2026-06-02
2026-06-01S, sale reported on Form 46,000$1.4M2026-06-02
2026-06-02S, sale reported on Form 45,537$1.2M2026-06-02
2026-06-10S, sale reported on Form 4643$160.1K2026-06-10
Source

Counted from the Form 4 filings this reporting owner (SEC CIK 1658379) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.

Source: U.S. Securities and Exchange Commission (EDGAR) and other official government data · Updated 2026-10-12 · For informational purposes only, not investment advice.
Privacy · Terms